From GlobeNewswire: 2025-04-16 14:12:00

The FDA has approved Scilex Holding Company’s request for the Orphan drug designation for Gloperba®, the first liquid oral version of colchicine, for the treatment of pericarditis, an inflammation of the pericardium. This new oral version provides more flexible dosing options for gout patients and aims to improve disease management. The Orphan drug designation is granted for rare diseases affecting fewer than 200,000 individuals in the U.S. Scilex Holding Company focuses on non-opioid pain management products and is dedicated to enhancing patient outcomes. For more information on Scilex Holding Company and its products, visit their website.



Read more at GlobeNewswire: Scilex Holding Company Announces FDA Has Approved Our